research News

CAMBRIDGE, Mass. — Amylyx Pharmaceuticals, Inc. today announced that the first participant has been dosed in ORION, a randomized, double-blind, placebo-controlled Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO]) for the treatment of progressive supranuclear palsy (PSP). The Phase 3 trial will enroll approximately 600 participants...
Quebec City, Canada – In people with amyotrophic lateral sclerosis (ALS), changes in neurons appear to activate immune cells. Lowering the inflammation could reduce the symptoms of the disease, according to a study led by Chantelle Sephton, a professor at Université Laval’s Faculty of Medicine. ALS is caused by the...
It has been shown that constitutively activated STAT3 is detected in many HCC cell lines and tissues. This suggests that STAT3 is a promising molecular target for HCC gene therapy. RNA interference (RNAi) is a post-transcriptional gene-silencing mechanism, in which the homologous RNA sequences could be introduced into cells that...
Liège, Belgium – An international research team led by scientists from the University of Liège has discovered an interesting new therapeutic target for the treatment of melanoma resistant to targeted therapies. Inhibition of the VARS enzyme could prevent this therapeutic resistance by resensitising tumours resistant to these targeted therapies. Melanoma...
Houston, Texas – Researchers at Baylor College of Medicine, University of Veterinary Medicine in Austria and Josep Carreras Leukemia Research Institute in Spain discovered that AML cells prevent the synthesis of proteins that suppress their growth by forcibly isolating the mRNAs that encode such proteins within structures known as P-bodies....
Houston, TX – Researchers at The University of Texas MD Anderson Cancer Center showed that altering the sequence of breast cancer treatment to administer radiation before mastectomy allowed for concurrent breast reconstruction surgery, which reduced the number of operations required, minimized treatment delays and improved patient satisfaction. The Phase II...